Alginate solution
By preparing low concentration aqueous solutions of monovalent metal salts of alginic acid with added salts like sodium chloride and aseptic filtration, the formulation addresses high endotoxin and viscosity reduction issues, ensuring stability and sterility for use in pharmaceutical or medical devices.
Patent Information
- Application Number
- JP2023019905
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2017-03-07
- Filing Date
- 2023-02-13
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2038-03-06
AI Technical Summary
Existing aqueous solutions of monovalent metal salts of alginic acid face issues with high endotoxin levels and viscosity reduction over time, making them unsuitable for ready-to-use, sterile, and storage-stable pharmaceutical or medical devices.
A method involving the preparation of a low concentration aqueous solution of monovalent metal salts of alginic acid, filtered aseptically, and concentrated under a non-oxidizing atmosphere, combined with the addition of salts like sodium chloride, to create a formulation with suppressed viscosity decrease over time, packaged in sealed containers or syringes.
The solution effectively reduces endotoxin levels and maintains viscosity stability for extended periods, enabling the formulation to be used as ready-to-use, sterile, and storage-stable pharmaceutical or medical devices.
Smart Images

Figure 0007581398000001 
Figure 0007581398000002 
Figure 0007581398000003
Abstract
Description
[Technical field]
[0001] The present invention relates to an aqueous solution preparation of a monovalent metal salt of alginic acid that is useful as a medicine or medical device, in particular, an aqueous solution preparation of a low-endotoxin monovalent metal salt of alginic acid having a weight-average molecular weight of 50,000 to 400,000 as determined by a GPC-MALS method, an aqueous solution preparation of a monovalent metal salt of alginic acid having a viscosity of 2700 mPa s or more as measured at 20°C using a rotational viscometer, an aqueous solution preparation of a monovalent metal salt of alginic acid that is inhibited from decreasing in viscosity over time, an aqueous solution preparation of a monovalent metal salt of alginic acid in a vial, and a ready-to-use aqueous solution preparation of alginic acid. The present invention relates to an aqueous solution preparation of a monovalent metal salt, a storage-stable aqueous solution preparation of a monovalent metal salt of alginic acid, a sterile aqueous solution preparation of a monovalent metal salt of alginic acid, an aqueous solution preparation of a monovalent metal salt of alginic acid filled in a sealed or airtight container, a prefilled syringe filled with an aqueous solution preparation of a monovalent metal salt of alginic acid, methods for producing them, an agent for suppressing viscosity decrease over time of an aqueous solution preparation of a monovalent metal salt of alginic acid, a method for suppressing viscosity decrease over time of an aqueous solution preparation of a monovalent metal salt of alginic acid, and a method for stabilizing an aqueous solution preparation of a monovalent metal salt of alginic acid. [Background technology]
[0002] It is known that cartilage regeneration or treatment can be performed by injecting an aqueous solution obtained by dissolving a freeze-dried preparation of a monovalent metal salt of alginic acid, such as a freeze-dried preparation of sodium alginate (hereinafter also referred to as Na alginate), into a cartilage defect in articular cartilage (Patent Document 1). On the other hand, industrial sodium alginate contains impurity electrolytes such as sodium chloride, sodium sulfate, sodium hydroxide, and sodium carbonate. These can be extracted with approximately 40% or more alcohol, allowing the impurity electrolytes to be removed. It has also been investigated how the viscosity, pH, structural viscosity, flow curve, capillary rise property, and other properties change when sodium chloride, sodium sulfate, etc. are added to an aqueous sodium alginate solution (Non-Patent Documents 1 and 2). In addition, a study was conducted on the viscosity decrease due to heating of sodium alginate in powder and solution form, and it was reported that while the viscosity of both decreased when heated, the rate of viscosity decrease was greater for the solution form (Non-patent documents 3 and 4). It has also been reported that the addition of sodium citrate to a sodium alginate solution suppresses the decrease in viscosity of the sodium alginate solution over time (Non-Patent Document 5).
[0003] As for sodium alginate aqueous solution, Alroid G oral solution 5% is available, which contains 5% sodium alginate by mass, sodium copper chlorophyllin, sodium dehydroacetate, paraben, sodium saccharin, ethanol and fragrance as a peptic ulcer drug. Patent Document 2 discloses a method for obtaining an alginate solution with endotoxin of 20 EU / g or less, and discloses that a 1.8% AG solution is prepared by adding a physiological solution (0.9% NaCl) to a low-viscosity alginate powder (sodium salt of alginic acid (E400)) and stirring the mixture to prepare a 1.8% AG solution. Similarly, Patent Document 3 discloses that a polysaccharide (e.g., alginate) is dissolved in a physiological solution (0.15 MNaCl in water) and vigorously stirred with a homogenizer to prepare an alginate sample containing 2% (w / v) alginate, and that the sample is sterilized by filtering through a 0.2 μm nylon membrane. The alginates used here are VLVG (very low viscosity) and LVG (low viscosity). Furthermore, Patent Document 4 discloses the use of a hypertonic liquid composition for the manufacture of a drug for promoting healing of surgical wounds or anastomotic openings used during perioperative periods, and discloses a hypertonic liquid composition consisting of 3% to 18% (w / v) sodium alginate with a molecular weight of 20,000 to 26,000, sodium chloride at 1.5% (w / v) or more, a sodium ion concentration of 6.9% (w / v), and the remaining amount of a normal injection solution. Patent Document 5 discloses a sterilized aqueous composition containing 0.5-10 wt% alginate and dissolved C2-7 mono- or dicarboxylate, with a viscosity of at least 300 cp at 25°C and a pH of 6.5-7.5, and in the examples, sodium chloride is added at 0.8% by mass. [Prior art documents] [Patent documents]
[0004] [Patent Document 1] WO2008 / 102855 publication [Patent Document 2] Patent No. 5684575 [Patent Document 3] US20150352144A publication [Patent Document 4] Special Publication No. 2010-514707 [Patent Document 5] Publication US8927524B [Non-patent literature]
[0005] [Non-Patent Document 1] Chemical Industry Journal Vol.61 No.7 1958 p.871-874 [Non-Patent Document 2] Chemical Industry Journal Vol.61 No.7 1958 p.874-877 [Non-Patent Document 3] Muroran Institute of Technology Research Report 1957 Vol.2 No.3 p.609-616 [Non-Patent Document 4] Muroran Institute of Technology Research Report 1960 Vol.3 p.443-449 [Non-Patent Document 5] Biomaterials 1985 Vol.6 p.68-69 Summary of the Invention [Problem to be solved by the invention]
[0006] The present invention aims to provide a low-endotoxin aqueous solution preparation of a monovalent metal salt of alginic acid, and more preferably to provide a low-endotoxin aqueous solution preparation of a monovalent metal salt of alginic acid that is inhibited from decreasing in viscosity over time. The present invention aims to provide a vial-packed aqueous solution preparation of a monovalent metal salt of low-endotoxin alginic acid. More preferably, the present invention aims to provide a vial-packed aqueous solution preparation of a monovalent metal salt of low-endotoxin alginic acid that is inhibited from decreasing in viscosity over time. The present invention aims to provide a ready-to-use, low-endotoxin aqueous solution preparation of a monovalent metal salt of alginic acid, more preferably a ready-to-use, low-endotoxin aqueous solution preparation of a monovalent metal salt of alginic acid that suppresses viscosity reduction over time. The present invention aims to provide a sterile, low-endotoxin aqueous solution formulation of a monovalent metal salt of alginic acid, and more preferably to provide a sterile, low-endotoxin aqueous solution formulation of a monovalent metal salt of alginic acid that is inhibited from decreasing in viscosity over time. The present invention aims to provide a low-endotoxin aqueous solution preparation of a monovalent metal salt of alginic acid filled in a sealed or airtight container. More preferably, the present invention aims to provide a low-endotoxin aqueous solution preparation of a monovalent metal salt of alginic acid filled in a sealed or airtight container, which inhibits a decrease in viscosity over time. The present invention aims to provide a pre-filled syringe filled with a low endotoxin alginic acid monovalent metal salt aqueous solution preparation. More preferably, the present invention aims to provide a pre-filled syringe filled with a low endotoxin alginic acid monovalent metal salt aqueous solution preparation that suppresses viscosity reduction over time. An object of the present invention is to provide an efficient method for producing a low-endotoxin aqueous solution preparation of a monovalent metal salt of alginic acid which is inhibited from decreasing in viscosity over time. An object of the present invention is to provide an agent for suppressing the decrease in viscosity over time of an aqueous solution preparation of a monovalent metal salt of low-endotoxin alginic acid. An object of the present invention is to provide a method for suppressing a decrease in viscosity over time of a low-endotoxin aqueous solution preparation of a monovalent metal salt of alginic acid. An object of the present invention is to provide a method for stabilizing a low-endotoxin aqueous solution preparation of a monovalent metal salt of alginic acid. [Means for solving the problem]
[0007] For example, in order to prepare ready-to-use preparations of pharmaceuticals and medical devices to be directly injected into the body, such as cartilage regenerating agents, the preparations must be sterile. When sterilizing an aqueous solution preparation of a monovalent metal salt of alginic acid to obtain a low-endotoxin aqueous solution preparation of a monovalent metal salt of alginic acid, sterilization involving heating or sterilization by electron beam or the like is not preferable because it causes the alginic acid to be reduced in molecular weight and the viscosity to decrease. On the other hand, in order to sterile filter (0.22 um filter) a highly viscous aqueous solution of alginic acid, such as that used as a cartilage regenerating agent, high pressure must be applied or a long period of time is required for filtration, both of which are undesirable for industrial production reasons. In addition, when a solid preparation of a monovalent metal salt of alginic acid, such as a freeze-dried preparation, is dissolved when used, appropriate equipment and facilities such as a clean bench are required to maintain sterility, and it may take time to dissolve the monovalent metal salt of alginic acid into a uniform, high-concentration solution, so a more convenient preparation is required. Therefore, after intensive research into a method for obtaining a ready-to-use aqueous solution formulation of a low-endotoxin monovalent metal salt of alginic acid, the present inventors surprisingly found that by first preparing a low-concentration aqueous solution of a monovalent metal salt of alginic acid, dissolving a predetermined amount of a salt selected from a monovalent metal salt and an ammonium salt in it, sterile filtering the resulting aqueous solution, filling it into a vial, and concentrating the concentration of the monovalent metal salt of alginic acid by drying in a non-oxidizing atmosphere using a conventional method, for example drying under reduced pressure, an aqueous solution formulation of a low-endotoxin monovalent metal salt of alginic acid in which viscosity reduction is suppressed, and that this aqueous solution formulation can efficiently suppress viscosity reduction over time, the present invention was completed based on this finding. Alternatively, a low-concentration aqueous solution of a monovalent metal salt of alginic acid is prepared, a predetermined amount of a salt selected from a monovalent metal salt and an ammonium salt is dissolved in it, the resulting aqueous solution is sterile filtered, and the aqueous solution of the monovalent metal salt of alginic acid is concentrated by drying in a non-oxidizing atmosphere by conventional methods, such as drying under reduced pressure, before being filled into a container such as a vial or syringe, and the solution is then filled into the container and sealed. This also provides the desired aqueous solution formulation of a monovalent metal salt of alginic acid with low endotoxin content, in which viscosity reduction is suppressed, and it has been confirmed that the viscosity reduction over time of this aqueous solution formulation can be efficiently suppressed.
[0008] That is, the present invention has the following aspects for achieving the above object. (1-1) A ready-to-use, storage-stable, sterile aqueous alginate solution formulation filled in a sealed or airtight container, which contains (a) a monovalent metal salt of low-endotoxin alginic acid having a weight-average molecular weight of 50,000 to 400,000 as determined by a GPC-MALS method, (b) a salt selected from monovalent metal salts and ammonium salts, and (c) water, wherein the concentration of component (a) is 1.5% by mass or more, the concentration of component (b) is 0.5 to 2% by mass, and the viscosity measured at 20°C using a rotational viscometer is 2700 mPa s or more. (1-2) An aqueous alginate preparation according to (1-1), wherein the salt selected from the group consisting of monovalent metal salts and ammonium salts is a water-soluble inorganic salt. (1-3) An aqueous alginate formulation according to (1-1) or (1-2), wherein the salt selected from the group consisting of monovalent metal salts and ammonium salts is sodium chloride. (1-4) An alginate aqueous solution formulation according to any one of (1-1) to (1-3), wherein the sealed container or airtight container is a vial. (1-5) A prefilled syringe of the alginate aqueous solution formulation of (1-1) or (1-3), wherein the sealed container or airtight container is a syringe. (1-6) An aqueous alginate preparation according to any one of (1-1) to (1-5), comprising the components (a), (b) and (c). (1-7) The viscosity reduction rate of the storage-stable formulation over a period of 3 months is 1) Less than 3% when stored at 2-8℃ 2) Less than 7% when stored at 25°C 3) Less than 47% when stored at 40°C An alginate aqueous solution preparation according to any one of (1-1) to (1-6) above,
[0009] (1-8) An aqueous solution formulation of an alginate salt according to any one of (1-1) to (1-7) for use as a medicine or a medical device. (1-9) An aqueous alginate preparation according to any one of (1-1) to (1-8), wherein the volume of the sealed or airtight container is 2 to 50 ml. (1-10) An aqueous alginate solution preparation according to any one of (1-1) to (1-9), wherein the amount of the aqueous alginate solution filled in a sealed or airtight container is 5 to 20 ml. (1-11) An aqueous alginate preparation according to any one of (1-1) to (1-10), in which the amount of the alginate filled in a sealed or airtight container is 50 to 500 mg as dry sodium alginate. (1-12) An alginate aqueous solution formulation according to any one of (1-9) to (1-11), wherein the sealed container or airtight container is a vial. (1-13) A prefilled syringe of the alginate aqueous solution preparation of (1-9) to (1-11), wherein the sealed container or airtight container is a syringe. (1-14) An aqueous alginate preparation according to any one of (1-1) to (1-13), in which the air in a sealed or airtight container is replaced with nitrogen gas. (1-15) The alginate aqueous solution formulation according to (1-14), wherein the sealed or airtight container is a vial. (1-16) A prefilled syringe of the alginate aqueous solution formulation of (1-14), wherein the sealed container or airtight container is a syringe. (2-1) A method for producing an aqueous alginate preparation according to any one of (1-1) to (1-16), comprising sterilizing or aseptically filtering an aqueous solution of a monovalent metal salt of alginic acid, the aqueous solution containing a salt selected from a monovalent metal salt and an ammonium salt, filling the solution into a container, and then concentrating the filtrate or freeze-drying the solution and aseptically reconstituting the filtrate and sealing the container. (2-2) A method for producing an alginate aqueous solution formulation according to (2-1), wherein the container is a vial. (2-3) A method for producing an aqueous alginate preparation according to any one of (1-1) to (1-16), comprising sterilizing or aseptically filtering an aqueous solution of a monovalent metal salt of alginic acid, the aqueous solution containing a salt selected from a monovalent metal salt and an ammonium salt, concentrating the filtrate, and then aseptically filling and sealing the container. (2-4) A method for producing an alginate aqueous solution formulation according to (2-3), wherein the sealed or airtight container is a vial. (2-5) A method for producing a prefilled syringe of an alginate aqueous solution formulation according to (2-3), wherein the container is a syringe. (3-1) An agent for suppressing viscosity decrease over time of an aqueous solution preparation of a monovalent metal salt of alginic acid, the agent comprising as an active ingredient a salt selected from monovalent metal salts and ammonium salts. (4-1) A method for suppressing a decrease in viscosity over time of an aqueous solution preparation of a monovalent metal salt of alginic acid, comprising adding a salt selected from a monovalent metal salt and an ammonium salt to the aqueous solution of a monovalent metal salt of alginic acid. (5) A ready-to-use, storage-stable, sterile vial filled with an aqueous alginate solution containing (a) a monovalent metal salt of low-endotoxin alginic acid having a weight-average molecular weight of 50,000 to 400,000 as determined by a GPC-MALS method, (b) a salt selected from monovalent metal salts and ammonium salts, and (c) water, wherein the concentration of component (a) is 1.5% by mass or more, the concentration of component (b) is 0.5 to 2% by mass, and the viscosity measured at 20°C using a rotational viscometer is 2700 mPa s or more. (6) A composition which is a ready-to-use, storage-stable, sterile aqueous solution of alginate salt filled in a sealed or airtight container, comprising (a) a monovalent metal salt of low-endotoxin alginate having a weight-average molecular weight of 50,000 to 400,000 as determined by a GPC-MALS method, (b) a salt selected from monovalent metal salts and ammonium salts, and (c) water, wherein the concentration of component (a) is 1.5% by mass or more, the concentration of component (b) is 0.5 to 2% by mass, and the viscosity measured at 20°C using a rotational viscometer is 2700 mPa s or more. Effect of the Invention
[0010] According to the present invention, there is provided an aqueous solution preparation of a monovalent metal salt of alginic acid that can efficiently suppress the decrease in viscosity of the monovalent metal salt of alginic acid over time even when stored or preserved for a long period of time. In addition, by adopting a process of subjecting an aqueous solution obtained by dissolving components (a) and (b) to sterile filtration and drying under a non-oxidizing atmosphere to concentrate the concentration of the monovalent metal salt of alginic acid, an aqueous solution preparation of a low-endotoxin monovalent metal salt of alginic acid that suppresses the decrease in viscosity can be obtained, and this aqueous solution preparation can enjoy a great advantage in industrial production in that the decrease in viscosity over time can be suppressed. [Brief description of the drawings]
[0011] [Figure 1] FIG. 1 is a graph showing the evaluation results of viscosity change over time at 25° C. / 60% RH (accelerated conditions) and 40° C. / 75% RH (severe conditions) of an aqueous solution of sodium alginate at a concentration of 2% by mass according to the present invention. [Diagram 2] FIG. 13 is a graph showing the inhibitory effect of sodium chloride on the viscosity decrease of aqueous sodium alginate preparations having various molecular weights stored at 40° C. / 75% RH in Example 2. [Diagram 3] FIG. 13 is a graph showing the viscosity reduction suppressing effect of sodium chloride when stored at 40° C. / 75% RH in Example 3. [Figure 4] FIG. 13 is a graph showing the viscosity reduction suppressing effect of sodium chloride when stored at 25° C. / 60% RH in Example 3. [Diagram 5] FIG. 13 is a graph showing the effect of inhibiting a decrease in the viscosity of sodium chloride during storage at 2 to 8° C. in Example 3. [Figure 6] FIG. 13 is a graph showing the change in viscosity over time of the sodium alginate aqueous solution preparation of the present invention in Example 4 when stored at 25° C. / 60% RH and during long-term storage at 2 to 8° C. [Figure 7] FIG. 13 is a graph showing the change in viscosity over time during long-term storage of the sodium alginate aqueous solution preparation of the present invention in Example 5 at 40° C. / 75% RH. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0012] Alginic acid, which is a component of the monovalent metal salt of alginic acid (a) used in the present invention, is a type of natural polysaccharide produced by extraction from seaweed and purification. It is also a polymer formed by polymerization of D-mannuronic acid (M) and L-guluronic acid (G). There are acid method and calcium method for industrial production of alginic acid, and although products produced by either method can be used in the present invention, those having a quantitative value by HPLC method within the range of 90 to 110% by mass after purification are preferable. As a commercially available product, for example, those sold by Kimika Co., Ltd. as the Kimika Algin series, preferably high-purity food and pharmaceutical grade products can be purchased and used. It is also possible to further purify commercially available products as appropriate before use. The monovalent metal salt of alginic acid used in the present invention is preferably one in which the hydrogen cation of the carboxyl group of alginic acid is ion-exchanged with a monovalent metal cation such as sodium or potassium, particularly an alkali metal cation. Of these, sodium alginate, potassium alginate, or a mixture thereof is preferred, and sodium alginate is particularly preferred.
[0013] The monovalent metal salt of alginic acid used in the present invention has a weight average molecular weight of 50,000 to 400,000 as determined by the GPC-MALS method. Of these, those having a weight average molecular weight of 100,000 to 400,000 are preferred. Here, it is more preferred that the upper limit of the weight average molecular weight is 300,000. Generally, polymeric substances derived from natural products do not have a single molecular weight, but are an aggregate of molecules with various molecular weights, so they are measured as a molecular weight distribution with a certain range. A typical measurement method is gel filtration chromatography. Typical information on molecular weight distribution obtained by gel filtration chromatography includes weight average molecular weight (Mw), number average molecular weight (Mn), and polydispersity ratio (Mw / Mn). The weight average molecular weight is determined by considering the contribution of large molecular weight polymers to the average molecular weight, and is expressed by the following formula. Mw = Σ(WiMi) / W =Σ(HiMi) / Σ(Hi) The number average molecular weight is calculated by dividing the total weight of the polymers by the total number of polymers. Mn = W / ΣNi = Σ(MiNi) / ΣNi =Σ(Hi) / Σ(Hi / Mi) Here, W is the total weight of polymers, Wi is the weight of the i-th polymer, Mi is the molecular weight at the i-th elution time, Ni is the number of molecules with molecular weight Mi, and Hi is the height at the i-th elution time.
[0014] It is known that the molecular weight of naturally occurring polymeric substances can vary depending on the measurement method (example of hyaluronic acid: Chikako YOMOTA et.al. Bull.Natl.Health Sci., Vol.117, pp135-139(1999), Chikako YOMOTA et.al. Bull.Natl.Inst. Health Sci., Vol.121, pp30-33(2003)). Regarding the measurement of the molecular weight of alginate, there are documents that describe a method of calculating from intrinsic viscosity and a method of calculating using SEC-MALLS (Size Exclusion Chromatography with Multiple Angle Laser Light Scattering Detection) (ASTM F2064-00 (2006), published by ASTM International). In addition, this document states that when measuring molecular weight by size exclusion chromatography (gel filtration chromatography), calculation from a calibration curve using pullulan as a standard substance is insufficient, and recommends the use of a multi-angle light scattering detector (MALLS) in combination (measurement by SEC-MALLS). Therefore, in the present invention, the weight average molecular weight (Mw) of alginate measured by SEC-MALLS is adopted (FMC Biopolymer, PRONOVA TM Here, SEC-MALLS is a method for determining the absolute molecular weight of a polymer by connecting a multi-angle light scattering detector (MALS) to GPC (SEC).
[0015] Therefore, when the molecular weight of an alginate is specified in this specification, it is the weight average molecular weight calculated by SEC-MALLS (GPC-MALS method) unless otherwise specified. Suitable measurement conditions for SEC-MALLS include, for example, using a calibration curve using pullulan as a standard substance. As the molecular weight of pullulan used as a standard substance, it is preferable to use at least 1.6 million, 788,000, 404,000, 212,000 and 112,000 as the standard substance. In addition, the eluent (200 mM sodium nitrate solution), column conditions, etc. can be specified. As the column conditions, it is preferable to use at least one column using a polymethacrylate resin-based packing material and having an exclusion limit molecular weight of 10 million or more. A representative column is TSKgel GMPWx1 (diameter 7.8 mm x 300 mm) (manufactured by Tosoh Corporation).
[0016] The monovalent metal salt of alginic acid used in the present invention preferably has a viscosity (20°C) of 50 to 20,000 mPa·s as a 1% solution measured by the Japanese Pharmacopoeia Viscosity Measurement Method using a rotational viscometer, more preferably 50 to 10,000 mPa·s, more preferably 100 to 5,000 mPa·s, more preferably 300 to 800 mPa·s, and even more preferably 300 to 600 mPa·s. As a ready-to-use preparation as a medicine or medical device, for example, the viscosity (20°C) measured by the Japanese Pharmacopoeia Viscosity Measurement Method using a rotational viscometer is preferably 2700 mPa·s or more, more preferably 3000 mPa·s or more, and even more preferably 3300 mPa·s or more. In addition, the monovalent metal salt of alginic acid used in the present invention should have an appropriate M / G ratio depending on the final use. The M / G ratio is preferably 0.4 to 2.0, more preferably 0.6 to 1.8, and even more preferably 0.8 to 1.6. Monovalent metal salts of alginic acid with these M / G ratios are useful for treating cartilage diseases. The monovalent metal salt of alginic acid used in the present invention has a reduced endotoxin level. It is preferable to use an alginic acid having an endotoxin level of less than 100 EU / g, more preferably less than 75 EU / g, and even more preferably less than 50 EU / g, as measured by the Japanese Pharmacopoeia Endotoxin Test. Such a reduced endotoxin level can be achieved by a known method or a method similar thereto. For example, the purification of sodium hyaluronate can be carried out by the method of Suga et al. (see, for example, Japanese Patent Application Laid-Open No. 9-324001), the purification of β1,3-glucan by the method of Yoshida et al. (see, for example, Japanese Patent Application Laid-Open No. 8-269102), the purification of biopolymer salts such as alginate and gellan gum by the method of William et al. (see, for example, Japanese Translation of PCT International Publication No. 2002-530440), the purification of polysaccharides by James et al. (see, for example, the pamphlet of International Publication No. 93 / 13136), the method of Lewis et al. (see, for example, the specification of U.S. Patent No. 5,589,591), the purification of alginate by the method of Herman Frank et al. (see, for example, Appl Microbiol Biotechnol (1994) 40:638-643), or methods similar thereto. The low endotoxin treatment of the present invention is not limited to these, and may be carried out by known methods such as washing, filtration with a filter (endotoxin removal filter, charged filter, etc.), ultrafiltration, purification using a column (endotoxin adsorption affinity column, gel filtration column, column with ion exchange resin, etc.), adsorption to hydrophobic substances, resins or activated carbon, organic solvent treatment (extraction with organic solvent, precipitation / sedimentation by adding organic solvent, etc.), surfactant treatment (see, for example, JP-A-2005-036036, etc.), or by appropriately combining these. These treatment steps may be appropriately combined with known methods such as centrifugation. It is desirable to appropriately select the method according to the type of alginic acid, etc.
[0017] The monovalent metal salts and ammonium salts used as component (b) of the present invention include water-soluble inorganic salts. Among these, the monovalent metal salts include salts of monovalent metals such as sodium and potassium, and particularly water-soluble salts of alkali metals. Specifically, inorganic salts include hydrochlorides, sulfates, and nitrates of alkali metals. Among these, hydrochlorides are preferred, and sodium chloride and potassium chloride are particularly preferred. Most preferred is sodium chloride. As the ammonium salt, water-soluble ammonium chloride is preferably used. In the present invention, the mass ratio of component (a) / component (b) is preferably 100 / 70 to 100 / 10, more preferably 100 / 60 to 100 / 20, and most preferably 100 / about 45. When component (b) is sodium chloride, it is most preferable to mix component (b) with component (a) so that the sodium chloride concentration in the ready-to-use preparation is equivalent to that of physiological saline.
[0018] In the alginate aqueous solution preparation of the present invention, the concentration of component (a) is 1.5% by mass or more, and the concentration of component (b) is 0.5 to 2% by mass. The preferred concentration of component (a) depends on the molecular weight of the alginic acid used, and when ALG-1 (average molecular weight of 250,000 by GPC-MALS method) described in the examples below is used, it is preferably 1.5% by mass to 3% by mass, more preferably 1.8% by mass to 2.5% by mass, and most preferably 2% by mass. When ALG-2 (average molecular weight of 150,000 by GPC-MALS method) described in the examples below is used, it is preferably 2% by mass to 5% by mass, more preferably 2.5% by mass to 4% by mass, and most preferably 3.5% by mass. When alginic acid having an average molecular weight of 72,000 by GPC-MALS method is used, it is preferably 3% by mass to 7% by mass, more preferably 4% by mass to 6% by mass, and most preferably 4.5% by mass to 5% by mass. The concentration of component (b) is preferably 0.5 to 2%, and more preferably 0.9%. The alginate aqueous solution preparation of the present invention may contain sugars such as mannitol, xylitol, and sucrose as additional components as long as the performance is not impaired, but is preferably composed of only components (a), (b), and water (c). On the other hand, the alginate aqueous solution preparation of the present invention preferably does not contain C2-7 mono- or dicarboxylate. Also, the alginic acid aqueous solution preparation of the present invention preferably does not contain sodium citrate. Also, the alginic acid aqueous solution preparation of the present invention preferably does not contain calcium salt. Also, the alginic acid aqueous solution preparation of the present invention is preferably one in which alginic acid is not crosslinked. The water used here is preferably water for injection. The viscosity of the alginate aqueous solution preparation of the present invention is usually 2700 mPa·s or more, preferably 3000 mPa·s or more, and more preferably 3300 mPa·s or more. The viscosity of the alginate aqueous solution formulation of the present invention can be measured according to a conventional method. For example, the viscosity can be measured using a coaxial double cylinder rotational viscometer, a single cylinder rotational viscometer (Brookfield type viscometer), a cone-plate type rotational viscometer (cone-plate type viscometer), etc., in the rotational viscometer method. It is preferable to follow the viscosity measurement method of the Japanese Pharmacopoeia (16th edition). In the present invention, it is preferable to perform the viscosity measurement under a condition of 20°C. For example, when measuring using a cone-plate type viscometer, the measurement can be performed under the following measurement conditions. The sample solution is prepared using MilliQ water. The measurement temperature is 20°C. The rotation speed of the cone-plate type viscometer is 1 rpm when measuring a 1% solution of monovalent metal alginate, and 0.5 rpm when measuring a 2% solution, and is determined based on this as a guide. When measuring a 1% solution of monovalent metal alginate, the measurement is performed for 2 minutes, and the average value from 1 minute to 2 minutes is taken. When measuring a 2% solution, the measurement is performed for 2.5 minutes, and the average value from 0.5 minutes to 2.5 minutes is taken. The test value is the average of three measurements. In the present invention, the viscosity was measured using a rotational viscometer, Rheostress RS600 (manufactured by Thermo Haake GmbH), with a biaxial cylindrical metal cup, at 20°C for 3 minutes, as described in the Examples below. The average value from 1 minute to 2 minutes after the start was recorded as the measured value.
[0019] The alginate aqueous solution formulation of the present invention is preferably stored refrigerated, preferably at 2 to 8°C. Refrigerated storage inhibits decomposition of the monovalent metal salt of alginic acid, and inhibits viscosity reduction. The alginate aqueous solution formulation of the present invention preferably has a shelf life or expiration date of 2 or 3 years when stored at 2 to 8°C. The viscosity reduction rate of the alginate aqueous solution formulation of the present invention after storage at 2 to 8°C for 2 years is usually less than 40%, preferably less than 30%, and more preferably less than 20%. The viscosity reduction rate can be extrapolated from accelerated test results, statistical processing, etc. The aqueous alginate preparation of the present invention preferably has storage stability. In the present invention, the term "storage stability" means that the viscosity reduction rate of the preparation after storage for 3 months under each of the following conditions is: 1) Less than 3% when stored at 2-8℃ 2) Less than 7% when stored at 25°C and 60% humidity. 3) Less than 47% when stored at 40°C and 75% humidity. It means that one of the following is satisfied. When stored at 2 to 8°C, the preferred viscosity reduction rate after three months is less than 2%, more preferably less than 1.5%; when stored at 25°C and a humidity of 60%, the preferred viscosity reduction rate after three months is less than 6%, more preferably less than 5%; and when stored at 40°C and a humidity of 75%, the preferred viscosity reduction rate after three months is less than 45%, more preferably less than 43%.
[0020] The alginate aqueous solution preparation of the present invention can be used as a medicine or medical device. Specifically, it can be used as a medicine or medical device for use as a cartilage regenerating agent, a cartilage disease treating agent, a cartilage damage filling agent, an intervertebral disc disease treating agent, and a meniscus disease treating agent. The alginate aqueous solution preparation of the present invention is prepared so as to be ready-to-use, but it can also be used as a solution with a concentration and viscosity suitable for the intended use by adding a solvent such as water for injection or physiological saline. The solution can also be used by impregnating a carrier such as a sponge. In addition, the solution can be used by adding a crosslinking agent such as a calcium chloride solution to the solution to gel it. In addition, the alginate aqueous solution of the present invention can be taken out of a container such as a vial and used as it is or after dilution to apply to the affected area. A preferred method for producing the aqueous alginate preparation of the present invention will now be described. That is, it is preferable to produce the alginate by a method in which an aqueous solution obtained by dissolving (a) a monovalent metal salt of alginic acid and (b) a salt selected from a monovalent metal salt and an ammonium salt is sterile filtered, filled into a container such as a vial, and then concentrated to a predetermined concentration by drying. Alternatively, the solution can be prepared by sterile filtering an aqueous solution obtained by dissolving (a) a monovalent metal salt of alginic acid and (b) a salt selected from a monovalent metal salt and an ammonium salt, filling the solution into a container such as a vial, and then freeze-drying the solution and reconstituting the solution with water under aseptic conditions. Alternatively, the composition can be produced by subjecting an aqueous solution obtained by dissolving (a) a monovalent metal salt of alginic acid and (b) a salt selected from a monovalent metal salt and an ammonium salt to sterile filtration, concentrating the solution to a predetermined concentration by drying, and then filling the solution into a container such as a vial or syringe. Alternatively, the solution can be produced by sterile filtering an aqueous solution obtained by dissolving (a) a monovalent metal salt of alginic acid and (b) a salt selected from a monovalent metal salt and an ammonium salt, and then filling the solution into a container such as a vial or a syringe.
[0021] More specifically, the components (a) and (b) are dissolved in water for injection to prepare an aqueous solution. In this case, the concentration of the monovalent metal salt of alginic acid, which is the component (a), is preferably 0.1% by mass to 1.4% by mass, more preferably 0.2% by mass to 1.3% by mass, and even more preferably 0.3% by mass to 1.2% by mass. The salt, which is the component (b), is preferably used in an amount such that the mass ratio of the component (a) / component (b) is 100 / 70 to 100 / 10, more preferably 100 / 60 to 100 / 20, relative to the component (a) used. However, it is essential to adjust the concentration of the component (b) to 0.5 to 2% by mass after concentration by drying. The order of addition of the components (a) and (b) to the water can be arbitrary, but it is preferable to add the components (a) and (b) in that order. The dissolution is usually carried out at room temperature, but in some cases the solution may be warmed, heated or cooled to about 40° C. Any stirrer may be used for dissolution. In the present invention, it is preferable that the viscosity (20°C) of the aqueous solution in which components (a) and (b) are dissolved is 40 to 800 mPa s. Here, the viscosity of the aqueous solution can be a value measured at 20°C using a rotational viscometer, Rheostress RS600 (manufactured by Thermo Haake GmbH), with a biaxial cylindrical metal cup. After dissolution, the present invention filters the aqueous solution, preferably by sterile filtration, to reduce endotoxin levels, preferably using a filtration filter, such as a 0.22 um filter. The sterile preparation of the present invention means, for example, a preparation that complies with the sterility test method specified in the Japanese Pharmacopoeia.
[0022] In the present invention, the aqueous solution in which components (a) and (b) are dissolved, or the aqueous solution in which components (a) and (b) are dissolved, is filled into a container such as a vial, and then, preferably, in a non-oxidizing atmosphere such as a nitrogen stream, it is dried by a conventional method, for example, drying under reduced pressure or drying under normal pressure, to concentrate the solution, and the concentration of the monovalent metal salt of alginic acid is 1.5% or more. Alternatively, in the present invention, the aqueous solution in which components (a) and (b) are dissolved, or the aqueous solution in which components (a) and (b) are dissolved, is dried by a conventional method, for example, drying under reduced pressure or drying under normal pressure, to concentrate the solution, and the concentration of the monovalent metal salt of alginic acid is 1.5% or more, and then, it can be filled into a container such as a vial or a syringe. The container such as a vial or a syringe in which the aqueous solution of the monovalent metal salt of alginic acid of the present invention is filled is preferably one having a capacity of 2 to 50 ml. The amount of the aqueous solution of the monovalent metal salt of alginic acid of the present invention to be filled is preferably about 1 to 90% of the capacity of a container such as a vial or syringe. For example, the amount of the aqueous solution of alginate to be filled into a container may be 5 to 20 ml. The amount of the alginate to be filled into a container may be 50 to 500 mg, preferably 50 to 150 mg, and more preferably 90 to 110 mg, of dry sodium alginate. After the concentration is completed or after the container is filled, it is preferable to replace the air in the container such as a vial with nitrogen gas, preferably dry nitrogen gas, and then seal the container with a cap, seal, or the like. The cap used for the vial is preferably made of rubber, particularly brominated butyl rubber. In addition, the vial may be made of various commercially available materials such as glass vials. The inner wall of the vial may also be coated with silicone or the like. The sealed or airtight container in which the aqueous solution formulation of the present invention is filled may be a vial, but instead of the vial, an ampoule, a syringe, a soft bag, or the like may also be used, and the vial or syringe is preferable. When a syringe is used, it can be used immediately as a prefilled syringe (ready-to-use), which is more convenient.
[0023] The present invention further provides an agent for suppressing viscosity decrease over time of an aqueous solution preparation of a monovalent metal salt of alginic acid, the agent comprising a salt selected from monovalent metal salts and ammonium salts, and a method for suppressing viscosity decrease over time of an aqueous solution preparation of a monovalent metal salt of alginic acid, the method comprising adding a salt selected from monovalent metal salts and ammonium salts to the aqueous solution preparation of a monovalent metal salt of alginic acid. In these embodiments, component (b), which is a salt selected from monovalent metal salts and ammonium salts, is preferably used relative to component (a), which is a monovalent metal salt of alginic acid, in a mass ratio of component (a) / component (b) in the range of 100 / 70 to 100 / 10, more preferably 100 / 60 to 100 / 20, thereby making it possible to suppress a decrease in viscosity over time of the aqueous solution preparation of a monovalent metal salt of alginic acid. The present invention also provides a method for stabilizing an aqueous solution formulation of a monovalent metal salt of alginic acid, comprising the steps of sterile filtering an aqueous solution obtained by dissolving components (a) and (b) and drying the aqueous solution under a non-oxidizing atmosphere to concentrate the concentration of the monovalent metal salt of alginic acid. EXAMPLES
[0024] Next, the present invention will be described more specifically with reference to examples, but the present invention is not limited to these. Example 1 A sodium alginate aqueous solution formulation was prepared by the following method. (1) Method for preparing sodium alginate aqueous solution Purified sodium alginate (purchased from Kimika Co., Ltd.: ALG-1 (average molecular weight 250,000: measured by GPC-MALS method: purity (quantitative value) 98%: viscosity (1% by mass solution, 20°C) 525 mPa s: M / G ratio 1.2), sodium chloride (manufactured by Merck Ltd.), and water (water for injection: manufactured by Otsuka Pharmaceutical Co., Ltd.) were used. Purified sodium alginate and sodium chloride were placed in a sterilized 1-2 L container together with water for injection, and the mixture was stirred at room temperature to dissolve, thereby preparing an aqueous solution of sodium alginate with a concentration of 1%. Next, this prepared drug solution was subjected to sterile filtration using a 0.22 μm filter (manufactured by Millipore) in a clean bench. (2) Concentration The drug solution prepared by the above method was filled into a 20 ml glass vial so that each vial contained 102 mg of dry sodium alginate, and then concentrated in the usual manner using a freeze-drying apparatus. The air inside the vial was then replaced with dry nitrogen gas, and the vial was then capped and sealed to prepare an aqueous solution formulation containing 2% by mass of sodium alginate and 0.9% by mass of sodium chloride.
[0025] (3) Stability of sodium alginate aqueous solution formulations over time In order to evaluate the change in viscosity over time of the 2% by mass aqueous solution of sodium alginate obtained in (2) above, the solution was stored in a temperature- and humidity-controlled room at 25°C and 60% RH (accelerated conditions) and 40°C and 75% RH (severe conditions), and the change in viscosity over time was evaluated. The viscosity was measured using a rotational viscometer, Rheostress RS600 (manufactured by Thermo Haake GmbH), with a biaxial cylindrical metal cup. The viscosity was measured at 20°C for 3 minutes, and the average value from 1 minute to 2 minutes after the start was recorded as the measured value. (4) Results The results obtained are shown in FIG. From the results in Figure 1, it was found that at 25°C (accelerated conditions), the viscosity decrease is gradual, so it is possible to ensure stability for two years when stored in a cool place. In particular, it can be seen that under accelerated conditions of 25°C and 60% RH, the viscosity decrease rate over three months is less than 1%. In addition, from the results for two months at 40°C and 75% RH, the viscosity decrease rate over three months was estimated to be approximately 40%.
[0026] Example 2 According to the method of Example 1, aqueous sodium alginate formulations were prepared using sodium alginate having different molecular weights. (1) Preparation and concentration of sodium alginate aqueous solution Using purified sodium alginate ALG-1 (same as in Example 1) and ALG-2 (purchased from Kimika Co., Ltd.: average molecular weight 150,000: measured by GPC-MALS method), aqueous solutions of sodium alginate at 2% by mass (ALG-1) and 3.5% by mass (ALG-2) were prepared. The sodium chloride concentration was 0.9% by mass in both cases. (2) Stability of sodium alginate aqueous solution formulations over time In order to evaluate the change in viscosity over time of each of the sodium alginate aqueous solutions obtained in (1) above, they were stored in a constant temperature and humidity room at 40°C and 75% RH (severe conditions), and the change in viscosity over time was evaluated in accordance with the method of Example 1. (3) Results The results obtained are shown in FIG. The results of the harsh conditions in Figure 2 show that there is a possibility that stability can be guaranteed for two years when stored in a cool place. In addition, the viscosity reduction rates over three months for ALG-1 and ALG-2 estimated from the results of three weeks under the harsh conditions of 40°C and 75% RH were approximately 39% and 45%, respectively.
[0027] Example 3 Various freeze-dried sodium alginate preparations were prepared by the following method, and then aseptically reconstituted with water to give aqueous sodium alginate preparations. The viscosity over time of these preparations was measured and evaluated in the same manner as in Example 1. (1) Method for preparing sodium alginate aqueous solution The same purified sodium alginate, sodium chloride (Merck Co., Ltd.) and water (water for injection: Otsuka Pharmaceutical Co., Ltd.) as those used in Example 1 were used. Purified sodium alginate alone (sodium alginate 5.1 g / L) or purified sodium alginate and sodium chloride (sodium alginate 5.1 g / L:NaCl 2.25 g / L) were placed in a sterilized 1-2 L container together with water for injection and stirred at room temperature to dissolve, to prepare the bulk drug solution. Next, the raw drug solution to be used was subjected to sterile filtration using a 0.22 μm filter (manufactured by Millipore) in a clean bench, and then filled into 20 ml glass vials so that each vial contained 102 mg of dry sodium alginate.
[0028] (2) Freeze drying The glass vial filled with the aqueous sodium alginate solution was freeze-dried using a freeze-drying apparatus under the following conditions. Freezing and drying conditions: The material was cooled to -40°C over 270 minutes, and then held at this temperature for 600 minutes until completely frozen. The temperature was then raised to -10°C over 240 minutes, and the pressure inside the freeze-dryer was reduced to 3 Pa or less at this temperature. The material was then held for approximately 120 hours until the material was dried to a moisture content of approximately 2% by mass. After freeze-drying, the air in the vial was replaced with dry nitrogen gas, and then the vial was capped and sealed, and then subjected to the following tests. (3) Stability of 2% sodium alginate solution over time The freeze-dried sodium alginate obtained in (2) above was dissolved in water (water for injection: manufactured by Otsuka Pharmaceutical Co., Ltd.) to prepare the following 2% by mass aqueous sodium alginate solutions 1 and 2. Furthermore, a freeze-dried product of purified sodium alginate alone was dissolved in physiological saline to prepare the following 2% by mass aqueous sodium alginate solution 3. Aqueous solution 1: With NaCl during lyophilization: Prepared with water for injection (Example 3-1) Aqueous solution 2: No NaCl during lyophilization: Prepared with water for injection (Reference Example 3-2) Aqueous solution 3: No NaCl during freeze-drying: Prepared with saline (Reference Example 3-3)
[0029] The stability over time of these 2% by mass solutions of sodium alginate was evaluated by measuring the change in viscosity over time at 40° C. / 75% RH, 25° C. / 60% RH, and 2 to 8° C. The viscosity was measured in the same manner as in Example 1. The results obtained are shown in FIGS. From the results in FIG. 3, it can be seen that when NaCl is present during freeze-drying, the viscosity decrease is gradual (aqueous solution 1: Example 3-1: slope of viscosity decrease -548, viscosity decrease rate over 3 months is about 38%), and therefore the viscosity decrease over time can be suppressed. In contrast, when NaCl is not present during freeze-drying, the viscosity decrease over time is large (aqueous solution 2: Reference Example 3-2: slope of viscosity decrease -623, viscosity decrease rate over 3 months is about 49%), and it can be seen that the viscosity decrease over time cannot be suppressed even if NaCl is not present during freeze-drying and is added thereafter (aqueous solution 3: Reference Example 3-3: slope of viscosity decrease -702, viscosity decrease rate over 3 months is about 54%). It can be seen that the viscosity decrease rate over 3 months for the formulation of Example 3-1 is less than 47% under conditions of 40°C and 75% RH.
[0030] The results in Figure 4 also show that the presence of NaCl during freeze-drying can suppress viscosity decrease over time, but the absence of NaCl during freeze-drying leads to a large viscosity decrease over time, and that the absence of NaCl during freeze-drying and subsequent addition of NaCl cannot suppress viscosity decrease over time. It can also be seen that the formulation of Example 3-1 showed a viscosity decrease rate of less than 7% over 3 months under conditions of 25°C and 60% RH. From the results of Figure 5, it can be seen that the presence of NaCl during freeze-drying can suppress the viscosity decrease over time, but the absence of NaCl during freeze-drying leads to a large viscosity decrease over time, and that the absence of NaCl during freeze-drying and subsequent addition of NaCl cannot suppress the viscosity decrease over time. It can also be seen that the viscosity decrease rate over 3% for the formulation of Example 3-1 was less than 3% over 3 months when stored at 2 to 8°C.
[0031] Example 4 The stability over time of the 2% by mass sodium alginate solution (aqueous solution 1) prepared in Example 3-1 was evaluated by measuring the change in viscosity over time at 25° C. / 60% RH and 2 to 8° C. for up to 18 months. The viscosity was measured in the same manner as in Example 1. The results obtained are shown in FIG. From the results in Fig. 6, it was confirmed that when NaCl is present during freeze-drying, the aqueous solution formulation after reconstitution is stable for a long period of time. From the results of this test, it is found that the formulation of Example 3-1 shows an average viscosity reduction rate of about 6%, less than 7%, over three months under conditions of 25°C and 60% RH. It is also found that the formulation of Example 3-1 shows no substantial viscosity reduction over 18 months under storage conditions of 2 to 8°C, and the average viscosity reduction rate over three months is less than about 3%.
[0032] Example 5 1.6 kg of the prepared drug solution prepared in (1) of Example 1 and sterile filtered was aseptically filled into a 5 L infusion bag, and dry nitrogen gas was passed through the infusion bag, and the solution was appropriately heated and stirred in a clean bench while being concentrated at normal pressure to obtain a prepared drug solution containing 2% by mass of sodium alginate and 0.9% by mass of sodium chloride (lot 1). Except for changing the heating conditions, the same procedure was followed to obtain a prepared drug solution (lot 2). This drug solution was aseptically filled into a 20 mL glass vial, capped and sealed to obtain a sodium alginate aqueous solution formulation. Separately, the drug solution was aseptically filled into a 20 mL syringe, capped and sealed to obtain a prefilled syringe filled with a sodium alginate aqueous solution formulation. Here, the aseptic filling operation was performed in a clean bench. The 2% by mass sodium alginate solutions (lot 1 and lot 2) filled in vials were evaluated for stability over time at 40°C / 70% RH for up to two months based on the change in viscosity over time. The viscosity was measured in the same manner as in Example 1. The results obtained are shown in FIG. From the results of this test in FIG. 7, the viscosity reduction rates of the formulations of Example 5 (lot 1, lot 2) over three months, estimated from the results for two months at 40°C and 75% RH, were approximately 35% and approximately 37%, respectively, and were equivalent in stability to an aqueous solution formulation reconstituted with water after lyophilization.
Claims
1. The aqueous solution of a monovalent metal salt of alginic acid containing the monovalent metal salt is sterilized or aseptically filtered, and then filled into a container. (i) concentrating and sealing the filtrate; or (ii) freeze-drying the filtrate, then aseptically reconstituting it with water and sealing it; a monovalent metal salt of low-endotoxin alginic acid having a weight-average molecular weight of 50,000 to 400,000 as measured by GPC-MALS; (b) a monovalent metal salt; and (c) water. The alginate aqueous solution preparation is a ready-to-use, storage-stable, sterile alginate aqueous solution preparation filled in a sealed or airtight container, the concentration of component (a) being 1.5% by mass or more, the concentration of component (b) being 0.5 to 2% by mass, and the viscosity measured at 20°C using a rotational viscometer being 2700 mPa·s or more. The viscosity reduction rate of the alginate aqueous solution preparation over a period of three months is 1) Less than 3% when stored at 2-8°C; 2) Less than 7% when stored at 25°C; 3) Less than 47% when stored at 40°C; An alginate aqueous solution formulation that satisfies any one of the following requirements.
2. 1. An alginate aqueous solution preparation produced by a production method comprising sterilizing or aseptically filtering an aqueous solution of a monovalent metal salt of alginic acid containing a monovalent metal salt, filling the container with the filtrate, freeze-drying the filtrate, and then aseptically reconstituting the filtrate and sealing the container; wherein the alginate aqueous solution preparation contains (a) a monovalent metal salt of low-endotoxin alginic acid having a weight-average molecular weight of 50,000 to 400,000 as determined by GPC-MALS method, (b) a monovalent metal salt, and (c) water; wherein the concentration of component (a) is 1.5% by mass or more, the concentration of component (b) is 0.5 to 2% by mass, and the viscosity measured at 20°C using a rotational viscometer is 2700 mPa·s or more. The alginate aqueous solution preparation is filled in a sealed or airtight container and is ready-to-use, storage-stable, and sterile; and wherein the viscosity reduction rate of the alginate aqueous solution preparation over a period of three months is 1) Less than 3% when stored at 2-8°C; 2) Less than 7% when stored at 25°C; 3) Less than 47% when stored at 40°C; An alginate aqueous solution formulation that satisfies any one of the following requirements.
3. 1. An alginate aqueous solution preparation produced by a production method comprising sterilizing or aseptically filtering an aqueous solution of a monovalent metal salt of alginic acid containing a monovalent metal salt, concentrating the filtrate, and then aseptically filling and sealing a container, the alginate aqueous solution preparation comprising (a) a monovalent metal salt of a low-endotoxin alginic acid having a weight-average molecular weight of 50,000 to 400,000 as determined by a GPC-MALS method, (b) a monovalent metal salt, and (c) water, the concentration of component (a) being 1.5% by mass or more, the concentration of component (b) being 0.5 to 2% by mass, and the viscosity measured at 20°C using a rotational viscometer being 2700 mPa·s or more, the ready-to-use, storage-stable, sterile alginate aqueous solution preparation being filled in a sealed or airtight container, the rate of decrease in viscosity of the alginate aqueous solution preparation over a period of three months being: 1) Less than 3% when stored at 2-8°C; 2) Less than 7% when stored at 25°C; 3) Less than 47% when stored at 40°C; An alginate aqueous solution formulation that satisfies any one of the following requirements.
4. The alginate aqueous solution formulation according to any one of claims 1 to 3, wherein the monovalent metal salt of component (b) is sodium chloride.
5. The alginate aqueous solution formulation according to any one of claims 1 to 4, wherein the sealed or airtight container is a vial or a syringe.
6. The alginate aqueous solution formulation according to any one of claims 1 to 5, comprising the components (a), (b) and (c).
7. The alginate aqueous solution formulation according to any one of claims 1 to 6, for use as a medicine or medical device.
8. The alginate aqueous solution preparation according to any one of claims 1 to 7, wherein the volume of the sealed or airtight container is 2 to 50 ml.
9. The alginate aqueous solution preparation according to any one of claims 1 to 8, wherein the air in the sealed or airtight container is replaced with nitrogen gas.
10. The alginate aqueous solution formulation according to any one of claims 1 to 9, further comprising a sugar.
11. 1) Component (a) has a weight average molecular weight of 250,000 as determined by the GPC-MALS method and a concentration of 1.5% by mass to 3% by mass; 2) Component (a) has a weight average molecular weight of 150,000 as determined by the GPC-MALS method and a concentration of 2% by mass to 5% by mass; or 3) The alginate aqueous solution preparation according to any one of claims 1 to 10, wherein the component (a) has a weight average molecular weight of 72,000 as measured by GPC-MALS method and a concentration of 3% by mass to 7% by mass.
12. The alginate aqueous solution preparation according to any one of claims 1 to 11, wherein the mass ratio of component (a) / component (b) is 100 / 70 to 100 / 10.
13. The alginate aqueous solution formulation according to any one of claims 1 to 12, wherein the M / G ratio in component (a) is 0.4 to 2.
0.
14. The alginate aqueous preparation according to any one of claims 1 to 13, wherein the monovalent metal salt of alginic acid of component (a) has an endotoxin level of less than 100 EU / g as measured by the Japanese Pharmacopoeia Endotoxin Test.
15. 1) The shelf life or expiry date when stored at 2-8°C is 2 or 3 years, or 2) The alginate aqueous solution preparation according to any one of claims 1 to 14, which has storage stability such that the viscosity reduction rate after storage at 2 to 8°C for two years is less than 40%.
16. The alginate aqueous solution formulation according to any one of claims 1 to 15, which is produced by a production method comprising drying and concentrating the filtrate in a non-oxidizing atmosphere.
17. The alginate aqueous solution formulation according to any one of claims 1 to 16, wherein the monovalent metal salt of alginic acid of component (a) is sodium alginate.
18. The alginate aqueous solution formulation according to any one of claims 1 to 17, wherein the viscosity reduction rate of the alginate aqueous solution formulation is determined based on the viscosity measured at 20°C using a rotational viscometer.
19. The alginate aqueous solution formulation according to any one of claims 1 to 18, which is used as a pharmaceutical or medical device for use in a formulation selected from a cartilage regenerating agent, a cartilage disease treating agent, a cartilage damage filling agent, an intervertebral disc disease treating agent, and a meniscus disease treating agent.
20. A prefilled syringe containing the alginate aqueous solution preparation according to any one of claims 1 to 19.
Citation Information
Patent Citations
Measuring method for magnetic anisotropy constant k1
JP1981084575A
Stable injection containing 3-methyl-1-phenyl-2-pyrazolon-5-one
JP1988132833A
Injection containing polypreenyl-based compound
JP1990172913A
Injection of vancomycin
JP1999005743A
Use of hypertonic liquid compositions for the manufacture of drugs that promote wound healing
JP2010514707A
